Swiss Re Introduces Pioneering Guidelines for Longevity Drugs

In a groundbreaking move that signals the insurance industry's adaptation to emerging medical technologies, Swiss Re has become the first reinsurance company to establish comprehensive underwriting guidelines for longevity medications. This landmark decision, announced from their Basel headquarters, addresses the growing use of drugs such as metformin and rapamycin for life extension purposes.

The newly introduced guidelines form part of Swiss Re's August 2025 Life Guide update, specifically targeting medications originally developed for other purposes but now being used for longevity enhancement. The guidelines provide a structured framework for underwriters to assess the risks associated with these emerging treatments, acknowledging the uncertain long-term effects of such medications. Additionally, the update includes an improved calculator for chronic kidney disease and prostate cancer risks, demonstrating Swiss Re's comprehensive approach to risk assessment.

The reach of Swiss Re's new guidelines is substantial, impacting over 800 insurance companies across more than 100 countries. These companies collectively conduct approximately 23 million risk assessment inquiries annually using the Life Guide. The guidelines' implementation represents a significant shift in how the insurance industry approaches longevity enhancement technologies, setting a new standard for risk assessment in the age of life-extending medications.

The introduction of these guidelines marks a pivotal moment in the insurance industry's approach to longevity science. As the first major reinsurer to address this emerging field, Swiss Re's framework is likely to become the industry standard, influencing how insurance companies worldwide adapt to the growing trend of longevity enhancement. The guidelines also reflect the delicate balance between embracing medical innovation and maintaining prudent risk assessment practices in the insurance sector.